CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Estadual de Campinas (UNICAMP). Centro de Hematologia e Hemoterapia (HEMOCENTRO) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Graduated from the Faculty of Medicine of the University of São Paulo, SP (1992). PhD from the State University of Campinas, UNICAMP, SP (2001). Postdoctorate and Visiting Assistant Professor at MD Anderson Cancer Center, TX, USA (2014-2016). Areas of expertise: PET/CT and SPECT/CT in Oncology, Radioisotope Therapy, Nuclear Orthopedics. (Text provided by the author) (Source: Lattes Curriculum)
| Articles published in Pesquisa para Inovação FAPESP about the researcher: |
| Radiopharmaceutical synthesized in Brazil improves quality of life for prostate cancer patients |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The last decade has witnessed significant advances in the field of nuclear medicine therapy in Brazil with the approval of Lu-177 (for neuroendocrine tumors), Y-90 (for radioembolization) and recently Ra-223 (for bone metastases of prostate cancer). However, there is a great need for additional therapeutic options for patients with metastatic soft tissue prostate cancer. Based on the high…
The main objective of this research is to perform and supervise radiopharmacy studies related to developing the in house labeling of the PSMA molecule with gallium-68. This process will include the validation of the synthesis process and quality control of the final product and the evaluation of the stability of radiolabeled elements and other parameters. This labeling will be performed i…
The main objective of this research is to perform and supervise radiopharmacy studies related to developing the in house labeling of the fibroblast activation protein (FAPI) molecule first with gallium-68 and then with lutetium-177 for FAPITher for theranostic.This process will include the validation of the synthesis process and quality control of the final product and the evaluation of t…
Representing the RIDC CancerThera (FAPESP - process number: 2021/10265-8) and aware of the complex development of research on the theranostic approach to cancer (simultaneous therapy and diagnosis) and the need to disseminate scientific knowledge to society in an accessible, reliable, and uncomplicated way, we, Amira Al Dargham (undergraduate student in Medialogy/Unicamp) and Larissa Mans…
Representing the RIDC CancerThera (FAPESP - process number: 2021/10265-8) and aware of the complex development of research on the theranostic approach to cancer (simultaneous therapy and diagnosis) and the need to disseminate scientific knowledge to society in an accessible, reliable, and uncomplicated way, we, Amira Al Dargham (undergraduate student in Medialogy/Unicamp) and Larissa Mans…
Bone metastases from patients with prostate cancer are the greatest cause of death, reduction of quality of life and elevated treatment costs. Radium-223 dichloride or Ra223Cl2 is an alpha-emitting radioisotope (95%) of approximately 28 MeV. This radiotracer mimics calcium, which is an integral part of bone metabolism. Therapy with Ra223Cl2 (Ra-223) in patients with metastatic prostate ca…
| 6 / 3 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 2 / 2 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 12 / 9 | All research grants and scholarships |
| Associated processes | |